Literature DB >> 18639518

Interleukin-20 targets renal cells and is associated with chronic kidney disease.

Chi-Chen Wei1, Hsing-Hui Li, Yu-Hsiang Hsu, Chung-Hsi Hsing, Junne-Ming Sung, Ming-Shi Chang.   

Abstract

Interleukin (IL)-10 is an anti-inflammatory factor that suppresses renal fibrosis and improves renal function in CKD rats. IL-20 belongs to the IL-10 family; therefore, we sought to determine whether IL-20 is involved in CKD. CKD patients at stage five expressed significantly higher IL-20 in serum than controls. Immunohistochemical staining demonstrated that more IL-20 protein was expressed in the kidney tubular-epithelial cells, mesangial cells, and immune cells of CKD rats with a 5/6 nephrectomy. The lung, liver, and heart tissue of CKD rats also overexpressed IL-20. Thus, we treated two tubular epithelial cells, TKPTS and M-1 cells, with IL-20 to study its effects on CKD. IL-20 treatment induced apoptosis in these cells via caspase-3 activation. Incubating IL-20 with rat interstitial fibroblasts, NRK-49F cells, upregulated TGF-beta1 production, one key inducer for renal fibrogenesis. Therefore, IL-20 injured renal epithelial cells and induced fibroblasts to produce TGF-beta1 that hastened the progression of CKD.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18639518     DOI: 10.1016/j.bbrc.2008.07.039

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  A polymorphism of interleukin-22 receptor alpha-1 is associated with the development of childhood IgA nephropathy.

Authors:  Jin-Soon Suh; Seong H Cho; Joo-Ho Chung; Ahrim Moon; Yong-Koo Park; Byoung-Soo Cho
Journal:  J Interferon Cytokine Res       Date:  2013-05-09       Impact factor: 2.607

2.  Impact of kidney function and urinary protein excretion on pulmonary function in Japanese patients with chronic kidney disease.

Authors:  Yusuke Nakade; Tadashi Toyama; Kengo Furuichi; Shinji Kitajima; Noriyuki Ohkura; Akihiro Sagara; Yasuyuki Shinozaki; Akinori Hara; Kiyoki Kitagawa; Miho Shimizu; Yasunori Iwata; Hiroyasu Oe; Mikio Nagahara; Hiroshi Horita; Yoshio Sakai; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2013-12-15       Impact factor: 2.801

3.  IL-20 is involved in obesity by modulation of adipogenesis and macrophage dysregulation.

Authors:  Yu-Hsiang Hsu; Chih-Hsing Wu; Chiao-Juno Chiu; Wei-Ting Chen; Yi-Chieh Chang; Martin Wabitsch; Ming-Shi Chang
Journal:  Immunology       Date:  2021-08-30       Impact factor: 7.397

Review 4.  Fibrosis Related Inflammatory Mediators: Role of the IL-10 Cytokine Family.

Authors:  Erna Sziksz; Domonkos Pap; Rita Lippai; Nóra Judit Béres; Andrea Fekete; Attila J Szabó; Ádám Vannay
Journal:  Mediators Inflamm       Date:  2015-06-24       Impact factor: 4.711

5.  Anti-IL-20 monoclonal antibody inhibited inflammation and protected against cartilage destruction in murine models of osteoarthritis.

Authors:  Yu-Hsiang Hsu; Ya-Yu Yang; Man-Hsiang Huwang; Yun-Han Weng; I-Ming Jou; Po-Tin Wu; Tain-Yu Lin; Li-Wha Wu; Ming-Shi Chang
Journal:  PLoS One       Date:  2017-04-20       Impact factor: 3.240

6.  Interleukin-20 targets podocytes and is upregulated in experimental murine diabetic nephropathy.

Authors:  Yu-Hsiang Hsu; Hsing-Hui Li; Junne-Ming Sung; Wei-Yu Chen; Ya-Chin Hou; Yun-Han Weng; Wei-Ting Lai; Chih-Hsing Wu; Ming-Shi Chang
Journal:  Exp Mol Med       Date:  2017-03-31       Impact factor: 8.718

7.  Anti-IL-20 antibody improved motor function and reduced glial scar formation after traumatic spinal cord injury in rats.

Authors:  Jung-Shun Lee; Yu-Hsiang Hsu; Yi-Shu Chiu; I-Ming Jou; Ming-Shi Chang
Journal:  J Neuroinflammation       Date:  2020-05-14       Impact factor: 8.322

Review 8.  IL-20 in Acute Kidney Injury: Role in Pathogenesis and Potential as a Therapeutic Target.

Authors:  Tian-Yu Lin; Yu-Hsiang Hsu
Journal:  Int J Mol Sci       Date:  2020-02-03       Impact factor: 5.923

9.  Interleukin-19 mediates tissue damage in murine ischemic acute kidney injury.

Authors:  Yu-Hsiang Hsu; Hsing-Hui Li; Junne-Ming Sung; Wei-Ting Chen; Ya-Chin Hou; Ming-Shi Chang
Journal:  PLoS One       Date:  2013-02-26       Impact factor: 3.240

10.  Anti-IL-20 Monoclonal Antibody Suppresses Prostate Cancer Growth and Bone Osteolysis in Murine Models.

Authors:  Yu-Hsiang Hsu; Cheng-Ying Wu; Chung-Hsi Hsing; Wei-Ting Lai; Li-Wha Wu; Ming-Shi Chang
Journal:  PLoS One       Date:  2015-10-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.